Antibodies to tumour necrosis factor α as treatment for Crohn's disease

Lancet

Volumn 355, Issue 9207, 2000, Pages 858-860

  Bell, S ^a   Kamm, M A ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD4 ANTIGEN; CHIMERIC ANTIBODY; COMPLEMENT; CYCLOSPORIN; DNA ANTIBODY; DOUBLE STRANDED DNA; DRUG ANTIBODY; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ABSCESS DRAINAGE; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY COMBINING SITE; ANTIBODY TITER; ANTIGEN BINDING; ANUS FISTULA; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CROHN DISEASE; CYTOTOXIC T LYMPHOCYTE; DISEASE ACTIVITY; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG LEGISLATION; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INFECTION; LUPUS ERYTHEMATOSUS; LYMPHOMA; MACROPHAGE ACTIVATION; MEMBRANE BINDING; MOUSE; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN DOMAIN; QUALITY OF LIFE; REMISSION; RHEUMATOID ARTHRITIS; SERUM SICKNESS; T LYMPHOCYTE ACTIVATION; TERATOGENICITY;

EID: 0034635834     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)00442-0     Document Type: Note

References (15)

1. BJ Scallon MA Moore H Trinh DM Knight J Ghrayeb Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions Cytokine 7 1995 251 259
2. WA Stack SD Mann AJ Roy Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease [see comments] Lancet 349 1979 521 524
3. WJ Sandborn S Targan SB Wolf A randomized, double-blind, placebo-controlled, multi-centre trial of the engineered human antibody to TNF (CDP571) for the induction and maintenance of clinical improvement in patients with moderate to severely active Crohn's disease Gut 45 suppl V 1999 A133
4. SR Targan SB Hanauer SJ van Deventer A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disase cA2 Study Group N Engl J Med 337 1997 1029 1035
5. G D'Haens S Van Deventer R Van Hogezand Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial Gasroenterology 116 1999 1029 1034
6. DH Present P Rutgeerts S Targan Infliximab for the treatment of fistulas in patients with Crohn's disease N Engl J Med 340 1999 1398 1405
7. P Rutgeerts G D'Haens S Targan Effecacy and safety of retreatment with anti-tumor necrosis factor antibody (Infliximab) to maintain remission in Crohn's disease Gastroenterology 117 1999 761 769
8. SB Hanauer P Rutgeerts G D'Haens Delayed hypersenstivity to infliximab (Remicade) re-infusion after a 2–4 year interval without treatment Gastroenterology 116 1999 A731
9. FJ Baert PR Rutgeerts Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications Int J Colorectal Dis 14 1999 47 51
10. SJ Bickston GR Lichtenstein KO Arseneau RB Cohen F Cominelli The relationship between infliximab treatment and lymphoma in Crohn's disease Gastroenterology 117 1999 1433 1437
11. AJ Greenstein GE Mullin JA Strauchen Lymphoma in inflammatory bowel disease Cancer 69 1992 1119 1123
12. WR Connell MA Kamm M Dickson AM Balkwill JK Ritchie JE Lennard-Jones Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease Lancet 343 1994 1249 1252
13. WR Connell JP Sheffield MA Kamm JK Ritchie PR Hawley JE Lennard-Jones Lower gastrointestinal malignancy in Crohn's disease Gut 35 1994 347 352
14. WR Connell MA Kamm JK Ritchie JE Lennard-Jones Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 year of experience Gut 34 1993 1081 1085
15. I Dalum DM Butler MR Jensen Therapeutic antibodies elicited by immunization against TNF-alpha Nat Biotechnol 17 1999 666 669